Stream
Stories
-
CHMP recommends marketing authorization for Ruxolitinib Krka
On 12 November 2026 the CHMP adopted a positive opinion, recommending the granting of a marketing authorization for Ruxolitinib Krka, intended for the treatment of myelofibrosis, polycythaemia vera and graft-versus-host disease. The generic will be available as 5 mg, 10 mg, 15 mg and 20 mg tablets.
-
CHMP adopts positive opinion on Fondaparinux sodium Evumed
On 12 November 2026 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a marketing authorization for Fondaparinux sodium Evumed, a generic of Arixtra. The product is intended for prevention of venous thromboembolic events in adults undergoing major orthopaedic or abdominal surgery, immobilised patients, and for treatment of unstable angina, myocardial infarction, superficial-vein thrombosis, deep-vein thrombosis and pulmonary embolism.
-
CHMP adopts positive opinion on Donrafylix
On 12 November 2026 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorization for Donrafylix, a biosimilar insulin aspart intended for the treatment of diabetes mellitus. The applicant is Kuraci BV and Donrafylix will be available as a 100 units/ml solution for injection.
-
CHMP adopts positive opinion on Baxfendy
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on 12 November 2026, recommending marketing authorization for Baxfendy, a baxdrostat tablet for uncontrolled hypertension. The opinion was issued by the EMA for AstraZeneca AB.
-
CHMP adopts positive opinion on Aumseqa
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a marketing authorization for Aumseqa, a 55 mg film-coated tablet intended for first-line treatment of adult patients with advanced NSCLC harbouring EGFR exon 19 deletions or L858R mutations, and for treatment of EGFR T790M mutation-positive NSCLC. The applicant for the medicinal product is SFL Pharmaceuticals Deutschland GmbH.
-
Amyris to acquire sweet protein innovator Oobli
Amyris, Inc. announced it will acquire Oobli, a leading sweet protein innovator, to add a proven protein technology platform to its biomanufacturing capabilities. The acquisition is expected to close in the coming weeks, with all existing customer commitments and brand partnerships honored uninterrupted.
-
PAI pharma acquires nexus pharmaceuticals expanding sterile injectable portfolio
PAI pharma announced the acquisition of nexus pharmaceuticals, adding an established commercial portfolio of over 20 hospital injectable products. The deal builds on PAI's investment in domestic sterile manufacturing and expands its hospital-focused pharmaceutical portfolio.
-
Olympus announces CMS valuation and reimbursement rates for new ESD CPT codes
Olympus said the U.S. Centers for Medicare & Medicaid Services published final valuations and CY2027 Medicare reimbursement rates for two new Category I CPT codes, CPT 43498 for upper gastrointestinal ESD and CPT 45991 for lower gastrointestinal ESD, effective Jan. 1, 2027. The company noted the rates reflect the clinical complexity and physician work involved in ESD.
-
Orphalan expands TRADITiONAL study into China, first participant randomised worldwide
Orphalan SA announced the expansion of its Phase 3 TRADITiONAL Study into China, marking the first participant worldwide randomised at The Second Affiliated Hospital of Zhejiang University School of Medicine. The study evaluates once-daily trientine tetrahydrochloride versus D-penicillamine over 48 weeks.
-
Cold Spring Harbor Laboratory hosts 21st Double Helix Medals dinner
The 21st annual Double Helix Medals dinner raised $6.5 million for CSHL's biological research and education programs. The event honored Dr. Kevin J. Tracey and philanthropist Michael Milken.
-
AbbVie registers Phase 2b/3 study of ABBV-2294 in systemic sclerosis
The study plans to enroll 580 participants at about 200 sites worldwide, with a planned start date of December 11, 2026. It plans to evaluate the safety and efficacy of the combination of ABBV-722 and upadacitinib versus placebo over 52 weeks with optional extension periods.
-
Pfizer registers Phase 3 trial of berobenatide in women with stress urinary incontinence and obesity
The study, titled VESPER-SUI, plans to enroll 900 participants and has a planned start date of November 17, 2026. It aims to learn about the safety and effectiveness of berobenatide in adult women with stress urinary incontinence and obesity or overweight.